The drug Prevnar is a vaccine meant to prevent certain types of bacterial meningitis. It is typically administered to infants starting around 2 months of age. In randomized, double-blind clinical trials of Prevnar, infants were randomly divided into two groups. Subjects in group 1 received Prevnar, while subjects in group 2 received a control vaccine. After the second dose, 137 of 452 subjects in the experimental group (group 1) experienced drowsiness as a side effect. After the second dose, 31 of 99 subjects in the control group (group 2) experienced drowsiness as a side effect. Does the evidence suggest that a lower proportion of subjects in group 1 experienced drowsiness as a side effect than subjects in group 2 at the α = 0.05 level of significance?